Our products

The Company has created and continues to develop a rich pipeline of proprietary, flexible, tumour-targeting drug delivery systems with the potential to deliver new or existing and highly potent drugs within a pro-drug vehicle.

This pipeline of new drug candidates utilises unique mechanisms of action. The tumour is specifically targeted, identified and located. Once achieved the novel mechanism releases the active ‘warhead’, thus reducing side effects due to systemic contamination.

It is also believed that Incanthera drugs could be used as a first wave therapy to initiate tumour cell kill once a solid tumour cancer has been diagnosed. The Incanthera programs have the potential to increase the therapeutic window where such oncology treatments can be utilised.

Incanthera Pipeline Chart Ar2020

Scheduled for clinical trials

Sol, Incanthera’s lead asset, is a proprietary topical formulation designed to deliver into the skin an active known to treat solar keratosis and prevent the formation of skin cancers.

Studies on Sol’s permeation across the skin barrier and safety profile on human skin, announced in September 2020, surpassed expectations, strengthening the technology’s commercial potential and valuation.

Incanthera introduced Sol to a number of potential commercial partners in 2020, and has now prioritised discussions with two global cosmetic companies to licence Sol’s technology to commercial partners.

Sol, Incanthera’s lead asset, is a proprietary topical formulation designed to deliver into the skin an active known to treat solar keratosis and prevent the formation of skin cancers.

Studies on Sol’s permeation across the skin barrier and safety profile on human skin, announced in September 2020, surpassed expectations, strengthening the technology’s commercial potential and valuation.

Incanthera introduced Sol to a number of potential commercial partners in 2020, and has now prioritised discussions with two global cosmetic companies to licence Sol’s technology to commercial partners.

Despite advances in targeted therapy over recent years, the treatment of most adult solid cancers remains palliative rather than curative and represents a major unmet need.

Solid cancers, particularly aggressively growing ones, are supported by a network of blood vessels. Vascular Disrupting Agents (‘VDAs’) were specifically designed to destroy the vascular network, depriving the growing tumour of essential nutrients and thereby killing it. However, their inherent cardiac toxicity is an obstacle to their effective use in the clinic. EP0015 seeks to address this by releasing the VDA only at the tumour site. EP0015 was licensed in 2017 and is currently being prepared for Phase 1 Clinical trial.

Despite advances in targeted therapy over recent years, the treatment of most adult solid cancers remains palliative rather than curative and represents a major unmet need.

Solid cancers, particularly aggressively growing ones, are supported by a network of blood vessels. Vascular Disrupting Agents (‘VDAs’) were specifically designed to destroy the vascular network, depriving the growing tumour of essential nutrients and thereby killing it. However, their inherent cardiac toxicity is an obstacle to their effective use in the clinic. EP0015 seeks to address this by releasing the VDA only at the tumour site. EP0015 was licensed in 2017 and is currently being prepared for Phase 1 Clinical trial.

Equin is a quinone-based prodrug activated by the enzyme DT-diaphorase (‘DTD’) which itself is over-expressed in many solid tumours including breast, colon, liver, bladder, stomach, the central nervous system (‘CNS’), lung tumours and in melanomas.

The expression of DTD is increased up to 80-fold in primary non-small cell lung cancer (‘NSCLC’) relative to normal lung cells and up to 35-fold in NSCLC relative to small cell lung cancer (‘SCLC’) cell lines.

Equin has been designed to overcome limitations associated with previously proposed bioreductive agents including, stability, solubility, poor efficacy and unsuitable clinical regimes. Equin is in the pre-clinical stage of development.

Equin is a quinone-based prodrug activated by the enzyme DT-diaphorase (‘DTD’) which itself is over-expressed in many solid tumours including breast, colon, liver, bladder, stomach, the central nervous system (‘CNS’), lung tumours and in melanomas.

The expression of DTD is increased up to 80-fold in primary non-small cell lung cancer (‘NSCLC’) relative to normal lung cells and up to 35-fold in NSCLC relative to small cell lung cancer (‘SCLC’) cell lines.

Equin has been designed to overcome limitations associated with previously proposed bioreductive agents including, stability, solubility, poor efficacy and unsuitable clinical regimes. Equin is in the pre-clinical stage of development.

Duo-C focuses upon targeting colorectal cancer using duocarmycins, which are recognised for their extreme cytotoxicity, converted to a prodrug and designed to overcome their intrinsic toxicity and make them manageable and potentially useful in the clinical set up.

The prodrug is activated by CYP2W1, a catabolic enzyme over-expressed in colorectal cancer. Results to date show promising prospects for this new class of drug, demonstrating successful delivery of ultra-potent agents with acceptable toxicity profiles. Duo-C is in the late discovery (lead) phase.

Duo-C focuses upon targeting colorectal cancer using duocarmycins, which are recognised for their extreme cytotoxicity, converted to a prodrug and designed to overcome their intrinsic toxicity and make them manageable and potentially useful in the clinical set up.

The prodrug is activated by CYP2W1, a catabolic enzyme over-expressed in colorectal cancer. Results to date show promising prospects for this new class of drug, demonstrating successful delivery of ultra-potent agents with acceptable toxicity profiles. Duo-C is in the late discovery (lead) phase.